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Abstract
Linezolid is an effective antimicrobial agent to treat methicillin-resistant Staphylococcus aureus (MRSA). Resistance to
linezolid due to the cfr gene is described worldwide. The present study aimed to analyze the prevalence of the cfr–mediated
linezolid resistance among MRSA clinical isolates in our area. A very low prevalence of cfr mediated linezolid resistance was
found: only one bacteremic isolate out of 2 215 screened isolates. The only linezolid resistant isolate arose in a patient,
previously colonized by MRSA, following linezolid therapy. Despite the low rate of resistance in our area, ongoing
surveillance is advisable to avoid the spread of linezolid resistance.
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Introduction
Linezolid has been introduced into the medical practice to treat
Gram-positive infections, especially those related with staphylo-
coccal infections including methicillin resistance Staphylococcus
aureus (MRSA).
Since the introduction of linezolid in the clinical practice several
mechanisms of linezolid-resistance have been described. The
major mechanism of resistance is mediated by mutations in the V
domain of the 23S rRNA. The most common mutation found is
located in the position 2,576 (E.coli numbering). Other mutations
close to the 2,576 position could also confer linezolid resistance
[1,2]. Due to the presence of multiple copies of the 23SrRNA
gene, a relationship between the number of mutated genes and the
level of resistance is well established, and known as ‘‘gene dosage’’
[3]. Another mechanism involved in linezolid resistance is the
modification of ribosomal proteins L3 and L4 encoded by rplC and
rplD genes, respectively. Some of the mutations found in these
genes are concurrent with mutations in the V domain of the 23S
rRNA [4]. Finally, RNA methylation by two different methyl-
tranferases has been related to linezolid resistance: RlnM - a codon
insertion in the methyltransferase gene rlmN reduces linezolid
susceptibility in clinical S.aureus [5], and a methyltranferase
encoded by the cfr gene. The cfr gene is mostly plasmid-located
[6] and confers cross resistance to phenicols, lincosamides,
oxazolidinones, pleromutilines amd streptogramin A (PhLOPS
phenotype). Some outbreaks of crf-mediated linezolid-resistant
strains have been reported in the literature, such as the recent
outbreak described in Spain by Morales et al [7]. In this case, the
epidemic strain was involved in surgical site infections; ventilator-
assisted pneumonia; and primary bacteremia in an intensive care
unit, affecting a total of 12 patients.
The objective of our work was to evaluate the prevalence of cfr
gene among MRSA clinical isolates in Hospital Universitari de
Bellvitge (HUB) from 1999 to 2010.
Materials and Methods
In the HUB 2,215 clinical MRSA isolates from single patients
were isolated from 1999 to 2010. Antibiotic susceptibility to
cefoxitin, oxacillin, erythromycin, clindamycin, gentamicin, to-
bramycin, ciprofloxacin, tetracycline, rifampin, chloramphenicol,
vancomycin and teicoplanin was studied in all strains by the disc
diffusion method, following CLSI guidelines. Isolates resistant to
both clindamycin and chloramphenicol, potentially linezolid-
resistant, were screened for the cfr presence. Susceptibility to
linezolid was studied in this group by the disc diffusion method
and microdilution (0.06 mg/L to 128 mg/L) according to CLSI
guidelines. The presence of cfr gene was analyzed by PCR. Two
strains carrying the cfr gene and previously characterized [8] were
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used as controls. Linezolid-resistant strains were genotyped by
multilocus sequence typing (MLST), following the methodology
described by Enrigh et al. [9], sequence types (STs) were
determined by comparing with the MLST database (www.mlst.
net). Staphylococcal Chromosome Cassette mec (SCCmec) typing
and agr polymorphism were studied by PCR according to
previously published procedures [10,11].
Results and Discussion
Linezolid was introduced in the clinical practice in HUB during
2003. Linezolid prescription average in our hospital during the
2004–2010 period was of 0.28 defined daily dose (DDD)/100
patients-days, with a peak of 0.50 DDD/100 patients-days in
2009.
Only 16 MRSA isolates (0.7%) had the clindamycin and
chloramphenicol resistance profile. Linezolid MICs were #2 mg/
L in all but one strain which showed MIC of 8 mg/L and carried
the cfr gene. Summarized MICs and results are shown in table 1.
The linezolid resistant strain was isolated from a blood culture in
April 2009 from a 76 year-old man. The patient had been
admitted to the intensive care unit (ICU) in February 2009
because of complications derived from a laryngeal cancer surgery
performed on December 2008. The patient carried a nasal MRSA
on admittance. During March multiple antibiotics were adminis-
tered, including linezolid over 19 days, to treat a MRSA
respiratory low-tract infection. The initial respiratory MRSA
isolates as well as the nasal isolate were resistant to erithromycin,
clindamycin, gentamycin, tobramycin, ciprofloxacin, rifampin and
susceptible to chloramphenicol and linezolid. The linezolid-
resistant MRSA strain was isolated, after linezolid administration,
in a single central catheter blood culture and subsequently in
different respiratory samples, though no specific therapy was
adopted. The patient finally died on May 2009, from a cardiac
arrest of unknown etiology. The linezolid resistant isolate was also
resistant to erithromycin, clindamycin, gentamycin, tobramycin,
ciprofloxacin, rifampin and chloramphenicol and belonged to
clone ST228-MRSA-SCCmecI with agr type II. Linezolid suscep-
tible MRSA strains also belonged to clone ST228-MRSA-
SCCmecI. No further spread of the linezolid resistant strain to
other patients was detected.
Other reports worldwide described the presence of the cfr gene
in different S.aureus genotypes either of community, ST8-MRSA-
SCCmecIV and ST398-MRSA-SCCmecV [12,13], or nosocomial
origin, ST125-MRSA-SCCmecIVc [8]. Thus, the presence of this
mechanism of resistance in different S.aureus genotypes could
potentially be easily spread worldwide due to its plasmid location.
In the case reported here, we did not perform additional studies on
coagulase-negative staphylococci, isolated from the same patient or
from other patients admitted to the ICU, that could play a role as
potential reservoir of the cfr gene for MRSA strains.
In our series, overall linezolid resistance mediated by the cfr
gene is very low in this period (0.05%; 1/2,215), similar to other
surveillance studies [14]. Among clindamycin and chloramphen-
icol resistant strains, cfr-mediated linezolid resistance was 6.25%
(1/16). Kerenberg et al [15] found the cfr gene in 3% of
chloramphenicol-resistant strains of Staphylococcus spp. of animal
and human origin.
The disc-diffusion technique is not suitable to recognize
linezolid resistance mediated by the cfr gene with the current
CLSI or EUCAST breakpoints. In our experience, staphylococcal
isolates exhibiting a resistance phenotype to clindamycin, chlor-
amphenicol and linezolid could suggest for a possible presence of
cfr. However, further molecular investigations are needed due to
the low cfr prevalence (6.25%) observed in this studied population.
Other linezolid resistance mechanisms, non cfr-mediated, are
possible, but they do not necessarily involve clindamycin and
chloramphenicol resistance.
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